Bracco Gains Pediatric MRI Edge with FDA Approval for VUEWAY
Event summary
- Bracco received FDA approval to extend the use of VUEWAY® (gadopiclenol) for injection to neonates and infants.
- VUEWAY delivers effective contrast enhancement at half the gadolinium dose (0.05 mmol/kg) compared to other macrocyclic GBCAs (0.1 mmol/kg).
- Over 3.5 million doses of VUEWAY have been administered across approximately 900 customer sites in the U.S.
- The approval was based on data from study GDX-44-015 evaluating safety and efficacy in pediatric patients.
The big picture
This approval positions Bracco favorably within the diagnostic imaging market, particularly as concerns around gadolinium deposition and patient safety drive demand for lower-dose contrast agents. The move aligns with a broader trend towards personalized medicine and minimizing patient exposure to potentially harmful substances, especially in vulnerable populations like neonates. While the market for pediatric MRI is smaller than adult imaging, it represents a high-value segment with a focus on long-term patient outcomes.
What we're watching
- Adoption Rate
- The speed of adoption among pediatric imaging centers will depend on clinician comfort with the lower dose and perceived impact on workflow.
- Liability Risk
- Bracco’s exposure to litigation related to gadolinium retention and NSF will be closely monitored, especially given the expanded pediatric indication.
- Competitive Response
- Other contrast agent manufacturers will likely respond with their own lower-dose formulations or marketing campaigns to maintain market share.
Related topics